Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation

[1]  A. Kondo,et al.  Site‐specific protein labeling with amine‐containing molecules using Lactobacillus plantarum sortase , 2012, Biotechnology journal.

[2]  K. Ley,et al.  Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. , 2011, Blood.

[3]  D. Auguste,et al.  Complementary targeting of liposomes to IL-1α and TNF-α activated endothelial cells via the transient expression of VCAM1 and E-selectin. , 2011, Biomaterials.

[4]  V. Šubr,et al.  E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells , 2011, Journal of drug targeting.

[5]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[6]  Youngho Seo,et al.  The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. , 2011, Biomaterials.

[7]  K. Ulbrich,et al.  Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Roel Deckers,et al.  Ultrasound triggered, image guided, local drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[9]  M. Dewhirst,et al.  Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery , 2010, Molecular Cancer Therapeutics.

[10]  K. Ulbrich,et al.  Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker , 2010, Pharmaceutical Research.

[11]  Katherine W Ferrara,et al.  Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[12]  R. Khalil,et al.  Inflammatory cytokines in vascular dysfunction and vascular disease. , 2009, Biochemical pharmacology.

[13]  A. Bao,et al.  [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. , 2009, Nuclear medicine and biology.

[14]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  K. Higaki,et al.  Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. , 2008, International journal of pharmaceutics.

[16]  K. Ulbrich,et al.  Coating of adeno‐associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera , 2008, The journal of gene medicine.

[17]  A. Verkman,et al.  Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  M. Dewhirst,et al.  A Tracer Dose of Technetium-99m–Labeled Liposomes Can Estimate the Effect of Hyperthermia on Intratumoral Doxil Extravasation , 2006, Clinical Cancer Research.

[19]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[20]  T Ikeda,et al.  Jet formation and shock wave emission during collapse of ultrasound-induced cavitation bubbles and their role in the therapeutic applications of high-intensity focused ultrasound , 2005, Physics in medicine and biology.

[21]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[22]  E. Wisse,et al.  The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer , 2004, Gene Therapy.

[23]  M. Rots,et al.  A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. , 2004, Human gene therapy.

[24]  D. Curiel,et al.  Targeting ofAdenovirus via Genetic Modification of the Viral Capsid Combined with aProteinBridge , 2003, Journal of Virology.

[25]  P. Colarusso,et al.  The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. , 2003, Human Gene Therapy.

[26]  G. Molema.  Tumor Vasculature Directed Drug Targeting: Applying New Technologies and Knowledge to the Development of Clinically Relevant Therapies , 2002, Pharmaceutical Research.

[27]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[28]  C. Bertozzi,et al.  Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. , 2001, Biochemistry.

[29]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[30]  H. Sedlacek.  Pharmacological aspects of targeting cancer gene therapy to endothelial cells. , 2001, Critical reviews in oncology/hematology.

[31]  A. Sidoli,et al.  Production of a soluble and functional recombinant streptavidin in Escherichia coli. , 1998, Protein expression and purification.

[32]  F. Schildberg,et al.  De novo expression of the cell adhesion molecule E-selectin on gastric cancer endothelium , 1998, Langenbeck's Archives of Surgery.

[33]  David D Spragg,et al.  Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Fox,et al.  Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. , 1995, Journal of the National Cancer Institute.

[35]  K. Kopple,et al.  The soluble form of E-selectin is an asymmetric monomer. Expression, purification, and characterization of the recombinant protein. , 1994, The Journal of biological chemistry.

[36]  A. Poggi,et al.  Lymphocyte-endothelial cell adhesion molecules at the primary tumor site in human lung and renal cell carcinomas. , 1993, Journal of the National Cancer Institute.

[37]  A. Harris,et al.  A study of adhesion molecules as markers of progression in malignant melanoma , 1992, The Journal of pathology.

[38]  E. Wisse,et al.  The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer , 2008, Gene Therapy.

[39]  S. Fox,et al.  The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium , 2004, Breast Cancer Research and Treatment.

[40]  S. Felix,et al.  Sialyl Lewisx-liposomes as vehicles for site-directed, E-selectin-mediated drug transfer into activated endothelial cells , 2001, Cellular and Molecular Life Sciences CMLS.

[41]  K E Norman,et al.  P-selectin glycoprotein ligand-1 supports rolling on E- and P-selectin in vivo. , 2000, Blood.

[42]  N M Green,et al.  Avidin and streptavidin. , 1990, Methods in enzymology.

[43]  Green Nm,et al.  Avidin and streptavidin. , 1990 .